Trial · NCT05781516
Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD
NCT05781516, Not applicable, Unknown, Wen Zhang
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD. Trials, record NCT05781516. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05781516
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD
- NCT number
- NCT05781516
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 74 participants, estimated
- Lead sponsor
- Wen Zhang
- Conditions
- IgG4-related Disease With Eosinophilia
- Interventions
- Prednisolone, Baricitinib
- First posted
- 2023-03-23
- Last updated
- 2023-03-27
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The difference of recurrent rate of IgG4-RD between the two groups | 52 weeks | Clinical recurrence definition: any item of IgG4-RD Responder Index ≥2 (without treatment), or ≥ 3 (with treatment) or new organ involvement; with or without elevated serum IgG4 levels. |
| Secondary | The time of recurrence | 0-52 weeks | Clinical recurrence definition: any item of IgG4-RD Responder Index ≥2 (without treatment), or ≥ 3 (with treatment) or new organ involvement; with or without elevated serum IgG4 levels. |
| Secondary | The changes of IgG4-related disease Responder Index | 52 weeks | According to international multispecialty validation study of IgG4-related disease Responder Index (Version: 13, December, 2015), Responder Index ≥ 0, and higher scores mean a worse outcome. |
| Secondary | The changes of blood Eosinophil cells | 52 weeks | Percentages (%) and counts (109) of peripheral eosinophil cells |
| Secondary | The changes of serum IgG levels | 52 weeks | Level of serum IgG(g/L) |
| Secondary | The changes of serum IgG4 levels | 52 weeks | Level of serum IgG4(mg/dL) |
| Secondary | The changes of serum hsCRP level | 52 weeks | Level of serum high-sensitivity C-reactive protein level(mg/L) |
| Secondary | The changes of ESR | 52 weeks | Serum erythrocyte sedimentation rate(mm/h) |
| Secondary | The percentages of adverse events | 52 weeks | Adverse effect of drugs |
| Secondary | The changes of PGA | 52 weeks | Changes of patient global assessment from baseline, score (0-10, higher is worse) |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05781516
GET https://conductscience.org/api/trials/v1/NCT05781516/registered